Abstract
Nanoparticle internalisation is crucial for the precise delivery of drug/genes to its intracellular targets. Conventional quantification strategies can provide the overall profiling of nanoparticle biodistribution, but fail to unambiguously differentiate the intracellularly bioavailable particles from those in tumour intravascular and extracellular microenvironment. Herein, we develop a binary ratiometric nanoreporter (BiRN) that can specifically convert subtle pH variations involved in the endocytic events into digitised signal output, enabling the accurately quantifying of cellular internalisation without introducing extracellular contributions. Using BiRN technology, we find only 10.7-28.2% of accumulated nanoparticles are internalised into intracellular compartments with high heterogeneity within and between different tumour types. We demonstrate the therapeutic responses of nanomedicines are successfully predicted based on intracellular nanoparticle exposure rather than the overall accumulation in tumour mass. This nonlinear optical nanotechnology offers a valuable imaging tool to evaluate the tumour targeting of new nanomedicines and stratify patients for personalised cancer therapy.
Introduction: The Bioavailability Gap
For decades, the "Enhanced Permeability and Retention" (EPR) effect has served as the foundational principle of cancer nanomedicine. The theory suggests that nanoparticles naturally accumulate in tumors due to their leaky vasculature. However, clinical outcomes have remained inconsistent. This research, published in Nature Communications, argues that the field has been measuring the wrong metric: total tumor accumulation.
A tumor is a complex environment comprising blood vessels and an extracellular matrix. Nanoparticles sequestered in the matrix are effectively "parked" and cannot reach intracellular targets like DNA. This "bioavailability gap" explains why patients with similar levels of total drug accumulation can experience vastly different therapeutic results.
Methods: The Binary Ratiometric Nanoreporter (BiRN)
To bridge this gap, researchers engineered the Binary Ratiometric Nanoreporter (BiRN). This two-modular polymer system acts as a digital switch to isolate the signal of internalized particles.
- Module 1 (Always-ON): A near-infrared fluorophore that serves as a constant internal standard for tracking.
- Module 2 (OFF-ON): A pH-sensitive fluorophore that remains dark in the bloodstream and extracellular space (pH ~6.8) but "switches on" when the pH drops below 6.3—a transition that occurs within minutes of endocytosis.
By calculating the ratio between these signals (the "O/A signal"), the system generates a digitized output: 0 for extracellular space and 1 for intracellular space. This effectively removes the "noise" of particles that have reached the tumor but are not yet bioavailable.
Key Results: The "20% Rule" and Predictive Power
The study utilized various models, including A549 lung and 4T1 breast cancer lines, as well as Patient-Derived Xenografts (PDX). The findings revealed a stark reality: across different tumor types, only 10.7% to 28.2% of accumulated nanoparticles were actually internalized. The vast majority remained trapped in acellular regions.
Crucially, the researchers found that total accumulation is a poor proxy for success. Instead, therapeutic response correlated strongly with the BiRN intracellular signal. For the paclitaxel prodrug PDPA-PTX, the correlation between intracellular exposure and tumor inhibition was remarkably high (R = 0.8636, p < 0.0001).
Using BiRN as a companion diagnostic, the team stratified mice into "high" and "low" endocytosis groups. The "high" group showed significantly better tumor suppression and fewer metastases when treated with Doxil, proving that intracellular quantification can predict which patients will respond to treatment.
Discussion and Future Outlook
While the BiRN system provides a powerful tool for patient stratification, it faces limitations regarding optical depth in human subjects. The authors suggest that the underlying ratiometric logic could be adapted for deeper-penetrating modalities like PET or MRI. By shifting the focus from total tumor accumulation to true intracellular bioavailability, this technology paves the way for more effective, personalized nanotherapies.
Summary updated